Rapid Micro Biosystems, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rapid Micro Biosystems, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $49 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $122 tied up three years earlier. More money tied up than 92% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-29.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 64% of Healthcare companies in United States.
Cash Locked Ratio
$49For every $100 of sales, $49 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $122 tied up three years earlier.
More money tied up than 92% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$83Sales grew 96% in 3 years; of every extra $100 of sales, $83 became extra profit.
Higher than 78% of Healthcare companies in United States.
Asset Productivity Ratio
+96% / -61%In 3 years sales changed by +96% while total assets changed by -61%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-23.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+36%Cash, after subtracting all debt, equals 36% of its market value (net cash).
Higher than 72% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Rapid Micro Biosystems, Inc. made a loss over the last year. Rapid Micro Biosystems, Inc. owes $0.70 for every $1 it owns. Rapid Micro Biosystems, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRapid Micro Biosystems, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.20The share price is 2.20 times Rapid Micro Biosystems, Inc.'s book value per share, lower than 55% of Healthcare companies in United States.
Market cap
$39 MThe total market value of all of Rapid Micro Biosystems, Inc.'s shares at today's price (share price × number of shares), smaller than 76% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$18 MWhat Rapid Micro Biosystems, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.35Net worth divided by the number of shares. The share price of $0.78 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-141.7%Rapid Micro Biosystems, Inc. lost 141.7% of its shareholders' money over the last year, lower than 79% of Healthcare companies in United States.
Owes vs Owns
0.70×Rapid Micro Biosystems, Inc. owes $0.70 for every $1 it owns (moderate), higher than 72% of Healthcare companies in United States.
Dividend yield
NoneRapid Micro Biosystems, Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 25% a year on average over 3 years.
Profit growth
LossRapid Micro Biosystems, Inc. made a loss in each of the last two years.
Profit margin
-140.3%Rapid Micro Biosystems, Inc. lost $140 for every $100 of revenue.
Interest cover
Not coveredRapid Micro Biosystems, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashRapid Micro Biosystems, Inc. held $14 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rapid Micro Biosystems, Inc.: $39 M ÷ $18 M (30 Jun 2026) = 2.2.
What is Rapid Micro Biosystems, Inc.'s return on equity?
Rapid Micro Biosystems, Inc. lost 141.7% of its shareholders' money over the last year, lower than 79% of Healthcare companies in United States.
How much does Rapid Micro Biosystems, Inc. owe compared with what it owns?
Rapid Micro Biosystems, Inc. owes $0.70 for every $1 it owns (moderate), higher than 72% of Healthcare companies in United States.
Does Rapid Micro Biosystems, Inc. pay a dividend?
No. Rapid Micro Biosystems, Inc. does not currently pay a dividend.
Is Rapid Micro Biosystems, Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 25% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.